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Abstract
Worldwide, more than 550, 000 new cases of head and neck squamous cell carcinoma
(HNSCC) are estimated to occur annually, making it the sixth most common human ma‐
lignancy. Since their discovery in 2007, cancer stem cells (CSCs) in HNSCC have garnered
increased interest secondary to their properties of tumorigenicity, differenti- ation, prolif‐
eration, and self-renewal. CSCs are intrinsically more resistant to tradi- tional treatments
such as radiation and chemotherapy, contributing to potential metastasis and recurrence
of HNSCC. This chapter focuses first on normal head and neck stem cells, providing
background for the discussion of a number of topics pertaining to the study of HNSCC
CSCs including molecular biomarkers and clinical implications. Continued research to
elucidate the properties of CSCs will undoubt- edly expand our knowledge surrounding
the pathogenesis, metastasis, and relapse of HNSCC. Ultimately, a better understanding
of CSC biomarkers, signaling pathways, and mechanisms of resistance will improve
therapies and patient outcomes through targeted interventions.
Keywords: Head and neck squamous cell carcinoma, Stem cells, Cancer stem cells, Che‐
moresistance, Metastasis
1. Introduction
In the United States, over 53, 000 new cases of head and neck squamous cell carcinoma
(HNSCC) are estimated to occur each year, with roughly 11, 000 deaths annually [1]. Across
the globe, HNSCC has an annual incidence of over 550, 000 cases, making it the sixth most
common cancer worldwide. HNSCC accounts for 90% of the malignancies in the head and
neck region, affecting the nasal vestibule, nasal cavity, paranasal sinuses, nasopharynx, lips,
oral cavity, oropharynx, pharynx, hypopharynx, and larynx. The foundation of treatment for
head and neck cancer has been surgery and radiation therapy, while chemotherapy may also
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be employed as an adjunctive treatment. Advancements in surgical technique, radiation strat-
egies and technologies, as well as chemotherapeutic drugs have led to improvements in
patient’s overall quality of life. However, the prognosis for HNSCC has improved only mar-
ginally over the past thirty years, with the five-year survival rate remaining at 50% [2-4]. Even
after standard therapy, patients with HNSCC exhibit relatively high rates of local recurrence,
regional cervical lymph node recurrence, and to a lesser degree distant metastasis, all of which
contribute to significant morbidity and mortality [5]. Often, these recurrences and metastases
are more resistant to traditional treatment modalities such as chemoradiation. Unfortunately,
primary site recurrence occurs in 10-30% of all patients [6].
Traditional approaches to understanding and treating HNSCC are based on the stochastic
model of cancer, where all tumor cells are identical (Figure 1). More recently, the cancer stem
cell (CSC) hypothesis has gained increasing traction in explaining tumorigenesis [7]. This
theory proposes that cancer maintains a hierarchical order of cells, with only a small subpop-
ulation of CSCs capable of tumor initiation, propagation, and regeneration [8]. Conventional
therapies that target rapidly cycling cells are less effective in killing CSCs. CSCs also display
increased intrinsic resistance to chemotherapy and radiation therapy. As a result, CSCs are
likely to contribute to cancer relapse.
This review aims to provide a succinct yet thorough overview of our current basis for the CSC
hypothesis as it pertains to HNSCC. We will start with a brief discussion of the normal
epithelium of the head and neck region as well as our current understanding of normal
endogenous stem cells of the head and neck region. Evidence for the CSC hypothesis of
Figure 1. In the stochastic model, all tumor cells have equal abilities to propagate, initiate tumors, and seed metastases.
The heterogeneity of tumors in this model is derived from spontaneous phenotypic shifts. The emerging cancer stem
cell hypothesis dictates the hierarchical model, in which asymmetric division results in specific and well-defined popu‐
lations of cancer stem cells and other cancer cells that do not initiate tumors or seed metastases. These cells may consist
of populations with decreased proliferative ability (i.e., transit-amplifying cells) or post-mitotic differentiated cells
with no further proliferative ability or activity.
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HNSCC will include a discussion of the prospective markers for CSCs in HNSCC, as well as
a closer look at the cellular regulation of these CSCs and the clinical implications of these
cancer- initiating and propagating cells.
2. Head and neck stem cells in normal tissues
Stem cells are unique in their ability to maintain self-renewal, differentiate into multiple
lineage types in the same tissue, and display a high degree of proliferative potential [9]. The
somatic stem cell microenvironment or cellular “niche” is vital in maintaining the delicate
distinction between self-renewal and uncontrolled proliferation of stem cells [10]. Stem cells
and the extracellular matrix secrete factors to maintain the microenvironment, while inhibitory
signals from this local microenvironment provide necessary control of proliferation and
differentiation to sustain this important subpopulation of cells [11, 12]. Importantly, these
quiescent, undifferentiated somatic stem cells also depend on the niche for the transient
stimulatory signals necessary for cell division and tissue regeneration [13]. Unlike most of the
gastrointestinal tract, which contains a simple epithelial layer to allow for increased absorp-
tion, the oral cavity, pharynx, and esophagus are covered by a stratified epithelium that is
more similar in structure to other tissues such as skin [14]. The stratified epithelium is
composed of multiple layers of cell types oriented in order of increasing differentiation from
basal to superficial.
In the normal squamous stratified epithelium, stem cells are located in the basal layer. To
replenish the more superficial layers, these stem cells divide asymmetrically to self-renew and
produce cells to undergo subsequent differentiation and amplification [11]. Cell division in
stratified squamous epithelium results in differentiation, superficial cellular movement, strat-
ification, and ultimately, tissue turnover. In the stratified squamous epithelium, for example,
a layer of small, cuboidal, basal stem cells are responsible for cell division and regeneration
[15]. Moving superficially, these committed cells further differentiate to increase keratin
filament production, flatten, and decrease the size and volume of the nucleus and organelles.
The most superficial (corneal or superficial) layers of the oral mucosa demonstrate cell
flattening, mem- brane thickening, decreased desmosomes, and eventual sloughing of cells
into the oral cavity [16]. The hierarchical normal oral epithelium is renewed approximately
every 14–24 days [17]. Increasingly, endogenous oral cavity stem cells are theorized to precede
CSCs, as these are the only cells with life span sufficient to accumulate the genetic mutations
necessary for malignant transformation [18].
3. Head and neck stem cell markers
In contrast to other tissues or organ systems, relatively few markers have been identified or
characterized for normal endogenous stem cells of the head and neck region. To date, most of
our knowledge of normal head and neck stem cells is based largely on work on oral epithelial
The Role of Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma and Its Clinical Implications
http://dx.doi.org/10.5772/61151
99
stem cells (OESCs) and corollaries from the skin and hair follicle, which also maintain a
squamous stratified epithelium.
In the 1960s, the first experiments to identify potential stem cells in the oral mucosa utilized
pulse-chase experiments with tritiated-thymidine (3H-TdR) to elucidate cell turnover rates in
the skin and oral mucosa and identify label-retaining cells in the basal layer [19]. Of the few
candidate cell surface markers for OESCs, most are also expressed in other normal oral
epithelial basal cells, meaning that much of the research involving OESC markers has involved
purification rather than isolation of these cells [20]. Such work is often accomplished based on
sorting for cell markers and performing subsequent in vitro experiments to test the self-renewal
and proliferative properties of these subpopulations. So far, notable candidate oral stem cell
markers include keratins K5, 14, 15, and 19, β1- and α6-integrins, integrin α6β4, melanoma
chondroitin sulfate proteoglycan (MCSP), p75NGFR, B-cell-specific Moloney murine leukemia
virus integration site 1 (BMI1), and the p63 transcription factor (Table 1) [20-37].
Aida et al. performed telomere analysis of different cell types in normal lingual epithelium to
calculate normalized telomere:centromere ratios (NTCRs). Overall, the basal cell group dem-
onstrated the largest NTCR, with a smaller subgroup of these cells maintaining an exception-
ally large NTCR, suggesting the presence of stem cells. In general, stem cells are thought to
maintain relatively longer telomeres due to a lower telomere turnover rate as well as the
potential for telomere upregulation. In addition, samples from older patients contained rela-
tively shorter telomeres, confirming a measurable age-related progression. Finally, immuno-
histochemistry confirmed the presence of p27, p63, and K19 in the basal layer with relatively
scant staining for Ki-67, a well-known marker of cell proliferation [22].
In one study, the magnetic separation of oral human keratinocytes yielded a fraction of α6β
+CD71 cells that could regenerate a stratified oral epithelial equivalent in vitro. Unlike either
of the α6β +CD71+ or or α6β keratinocyte groups, α6β +CD71- cells also expressed the candidate
stem cell markers p63 and Keratin 19 and were negative for two recognized markers of
differentiation: cytokeratin 10 or involucrin [23].
Tao et al. demonstrate a method of enriching a subpopulation containing both potential stem
cells and transit amplifying cells through integrin-β1 adherence to collagen IV. While their
subsequent study of p63 expression could not confirm specificity for stem cells in the basal
layer, the ΔNp63α and ΔNp63β isoforms may be more specific markers for undifferentiated
or immature cells [21].
Through cell lineage mapping, Hogan and coworkers noted a K14+K5+Trp63+Sox2+ subpopu-
lation of long-term stem or progenitor cells located outside the taste buds that are capable of
differentiating into both mature taste bud receptor cells as well as keratinocytes. The authors
suggest that a similar model may apply to the taste buds of the circumvallate papillae and soft
palate, and that their work may prove a model system for future study of these endogenous
stem cells [24]. This same group isolated a population of undifferentiated tongue basal cells
using Krt5-eGFP transgenic mice that demonstrated self-renewal and differentiation to strati-
fied keratinized epithelial cells in vitro.
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Candidate
Normal Stem
Cell Marker
Site(s) Studied Function and Significance in Stem Cell Biology References
Keratin 5 Mouse tongue and soft
palate
ntermediate filament protein expressed by basal
epithelial cells, only small fraction may actually
replicate
[24,29,31]
Keratin 14 Mouse tongue and oral
mucosa
Intermediate filament protein expressed by basal
epithelial cells, only small fraction of these cells
may actually replicate
[24,29,32]
Keratin 15 Human hard palate Intermediate filament protein, marker of stem cells
in hair follicle bulge, expressed in deep tips of
palatal epithelial papillae
[33]
Keratin 19 Human hard palate and
gingiva
Intermediate filament protein, stem cell marker for
cells of hair follicle
[22,23,34,35]
β1-integrin Cultured human
epidermal,
buccal, and gingival
cells
Important in adhesion to extracellular matrix
proteins, increased in cells with higher colony-
forming efficiency
[21,36]
α6β4-integrin Human hard palate and
gingiva
Important in adhesion to basement membrane,
expressed on α6β4 CD71 basal cells capable of oral
epithelium regeneration
[23,33,34]
MCSP Human hard palate Cellular surface proteoglycan associated with
migration and invasion of melanoma cells,
important for maintenance of patterned
distribution and clustering of epidermal stem cells
[20,33,37]
p75NGFR Human esophageal,
buccal, gingival, and
laryngeal
epithelium
Low-affinity neurotrophin receptor in TNF receptor
superfamily important in proliferation, cell
migration, and tissue regeneration
[25-28]
p63 Rat palate and oral
mucosa, human tongue,
gingival and buccal
epithelium
Transcription factor with multiple isoforms
responsible for epidermal stem cell maintenance
and regulation
[21,22,24,34]
BMI1 Mouse lingual
epithelium
Protein involved with epithelial cell maintenance,
proliferation, and tissue regeneration
[29]
Table 1. The function and significance of candidate normal stem cell markers in the head and neck region.
The low-affinity neurotrophin receptor p75NGFR is a member of the tumor necrosis factor
receptor superfamily and has effects in cell survival, apoptosis, and intercellular signaling [25].
It has been put forth as a possible stem cell marker for neural crest, mesenchymal, esophageal,
oral mucosa [25], and most recently laryngeal epithelium [25, 26]. In addition, p75NGFR-positive
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basal keratinocytes are able to migrate and initiate regeneration of damaged buccal epithelium
[27]. Furthermore, expression of p75NGFR has been shown to be closely related to CSCs in
esophageal squamous cell carcinoma as well as laryngeal squamous cell carcinoma [26, 28].
Recent interest in lingual epithelial stem cells has provided some evidence that keratins K5
and K14 may not be specific stem cell markers in this system. Ueno and coworkers utilized
immunostaining to reveal that only a small fraction of these keratins K14/K5-positive cells were
actually replicating to supply epithelial cells [29]. Rather, this group identified a group of BMI1-
positive stem cells that maintain the epithelial cells and can regenerate after irradia- tion-
induced tissue injury. Curiously, these potential stem cells were located in the second or third
epithelial layer of the interpapillary pit of the filiform papillae. Increasingly, BMI1 is viewed
as a candidate marker for CSCs of the head and neck, with the potential for prognostic value
based on the location of this intracellular oncoprotein [30].
MCSP, melanoma-associated chondroitin sulfate proteoglycan; NGFR, nerve growth factor
receptor; TNF, tumor necrosis factor; BMI1, B-cell-specific Moloney murine leukemia virus
integration site 1
4. Origin of head and neck cancer stem cells
In most instances, HNSCC is caused by the accumulation of multiple genetic mutations based
on genetic predisposition, which is induced by environmental factors such as tobacco and
alcohol abuse or persistent human papilloma virus infection [38]. However, the alterations of
multiple molecular and cellular pathways that lead to the development and recurrence of
HNSCC are still not well understood. Recently, recurrence and therapeutic resistance of
HNSCC has been attributed to a subpopulation of self-sustaining, tumor-initiating CSCs. CSCs
are defined by several exclusive features that allow propagation as well as tumor formation
and maintenance. These features are: (1) differentiation, giving rise to heterogeneous progeny;
(2) self-renewal, which maintains a pool of stem cells which can expand; and (3) homeostatic
control, which accounts for tissue specificity [4].
Multiple possible origins for CSCs have been proposed wherein a population of self-renewing
cells are formed, leading to tumorigenesis (Figure 2) [39]. In one such scenario, normal stem
cells undergo mutations that diminish restraint on replication, thereby creating CSCs that are
unresponsive to environmental or intrinsic controls on self-renewal. Another potential source
of CSCs are the more differentiated progenitor cells, also known as transit-amplifying cells,
which maintain a more limited role in self-renewal yet are far more numerous than stem cells.
A third motif of CSC generation explains that well-differentiated, mature cells undergo muta-
tions to dedifferentiate and obtain greater self-renewal potential [5]. There is evidence that
these dedifferentiated HNSCC cells may undergo epithelial-mesenchymal transition and inva-
sion, leading to the development of cells with CSC- or mesenchymal characteristics [40].
New Aspects in Molecular and Cellular Mechanisms of Human Carcinogenesis102
5. Initial clues to the concept of head and neck cancer stem cells
The first “leukemia-initiating” CSCs were identified in 1994 by Dick and co-workers through
their work with acute myeloid leukemia [41]. In 2003, Al-Hajj et al. reported the first CSCs in
a solid tumor by separating a tumorigenic subpopulation of breast cancer cells based on the
surface cell markers CD44+/CD24-/low [42]. In 2007, a landmark study by Prince et al. described
a subpopulation of CD44+ tumor-initiating cells isolated from HNSCC, although the cell
surface markers CD44s and CD44v6 were subsequently described in a majority of normal head
and neck tissues as well as HNSCC [43, 44]. Other subpopulations of tumor-initiating cells
have since been identified in HNSCC that also fulfill the criteria for CSCs. Furthermore, several
of the putative markers of these CSC subpopulations have been linked to cancer recurrence
and therapeutic resistance, augmenting the evidence for the CSC hypothesis in HNSCC. Recent
interest in the identification of new and improved biomarkers for HNSCC CSCs has spiked
due to the prospect of using these tools to improve treatment approaches and overall mortality
in this deadly disease.
Figure 2. Potential origins for cancer stem cells include normal stem cells, progenitor cells, or fully differentiated cells.
To give rise to cancer stem cells, the progenitor and fully differentiated cells acquire mutations to reactivate genes re‐
sponsible for increased proliferative activity, cell-division, and dedifferentiation.
6. Cancer stem cell assays
The isolation and identification of CSCs is a hefty experimental challenge, as there is no
established protocol to verify putative CSCs. Current experimental goals aim to satisfy the
CSC criteria of both self-renewal as well as the capacity to develop heterogeneous cell lineages
capable of forming tumors identical to the original [45]. Isolation strategies attempt to exploit
the unique properties of CSCs that distinguish them from their differentiated progeny. Such
The Role of Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma and Its Clinical Implications
http://dx.doi.org/10.5772/61151
103
capacities include the efflux of vital dyes by multidrug transporters, enzymatic activity,
sphere-forming capacity in low attachment conditions, and the expression of cell surface
antigens [46]. There are currently four main strategies for isolation of CSCs: (1) detection of
side-population phenotypes by Hoechst 33342 exclusion, (2) sphere-formation assays, (3)
assessment of aldehyde dehydrogenase (ALDH) activity, and (4) identification of CSC-specific
cell surface markers [45]. To date, the most common modality in identifying HNSCC CSCs
relies upon the expression of membrane cell surface antigens present in stem-like cells. As a
result, most potential CSC populations are detected by immunohistochemistry or flow
cytometry. Many of these antigens were originally put forth as potential targets as a result of
their expression in normal stem cells [47, 48]. Herein, we present a review of the most promis-
ing putative HNSCC CSC markers: CD44, CD133, and ALDH. We also include a discussion
of CD24 and CD10.
Putative Cancer
Stem Cell Markers in
HNSCC Sites
Studied
Biological Function Significance in HNSCC Stem Cell
Biology
References
CD44 Surface glycoprotein involved in cell
migration and adhesion
Showed the ability to regenerate
tumor
in vivo but also abundantly expressed
in normal squamous epithelia of the
head and neck. Associated with Snail
(chemoresistance and radioresistance)
as well as high coexpression of BMI1
(important for self-renewal and
tumorigenesis)
[43,44,49,50,55]
CD133 (Prominin 1) Transmembrane glycoprotein
localized
on membrane protrusions and
microvilli
Correlated with lymph node
metastases and decreased overall
survival
[51,52,54,55]
ALDH Intracellular enzyme most
commonly found in the liver. ALDH
detoxifies
intracellular aldehydes through
oxidation
Tumor cells expressing relatively high
levels of ALDH have increased
tumorigenicity, stem-cell-related
genes, drug-resistant genes, and EMT-
related genes. Associated with high
co-
expression of Snail protein, which is
an EMT regulator and key factor in
self- renewal and tumorigenicity
[47,56,65]
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Putative Cancer
Stem Cell Markers in
HNSCC Sites
Studied
Biological Function Significance in HNSCC Stem Cell
Biology
References
CD24 Mucin adhesion molecule for P-
selectin and L1 expressed by pre-B
lymphocytes and neutrophils
during cell
development
Associated with increased
proliferation and invasion in vitro and
tumorigenicity in vivo, correlates with
increased resistance to
chemotherapeutic agents
[47,60,62]
CD10 Zinc-dependent
metalloendoprotease that cleaves
signaling peptides and is found in a
wide range of normal tissues
Described as a potential marker for
therapeutic resistance and tumor
recurrence in HNSCC
[64]
Table 2. The function, significance, and associations of putative cancer stem cell markers in HNSCC.
7. Putative head and neck cancer stem cell markers
7.1. CD44
CD44 is a surface glycoprotein involved in cell migration and adhesion. Prince et al. demon-
strated the ability of a subpopulation of CD44+ HNSCC cells to regenerate a tumor in vivo
after transplantation of as few as 5x103  cells into an immunocompromised mouse model
[44]. CD44+ cells have been shown to express a high level of BMI1, a prospective normal
stem  cell  bio-  marker  that  also  plays  a  key  role  in  self-renewal  and  tumorigenesis  in
malignancy [49, 50]. While CD44 was the first CSC marker established for HNSCC, its role
has since come into question. In contrast to earlier studies involving CD44, recent studies
have demonstrated the abundant expression of CD44 in most HNSCC tumor cells. In one
such study, CD44 was present in 80-100% of tumor cells [43]. However, according to the
hierarchical model, only a small subset of cells within malignant tissue that are able to generate
tumors should stain positive for CSC markers. Furthermore, high percentages of CD44+ cells
have been identified in normal squamous epithelia of the head and neck, with up to 60–
95% of normal head and neck epithelial cells demonstrating CD44 positivity. Although the
role of CD44 in HNSCC has raised some questions, this protein may still prove a valua‐
ble role in the identification of CSCs when used in combination with other markers. In the
2009 study by Chen et  al.,  not only did knockdown of Snail  expression in CD44+ALDH+
cells  decrease  tumor  invasion  and  colony  formation,  but  it  also  significantly  increased
sensitivity to chemotherapy and radiotherapy. Specifically, following seven days of Snail
siRNA treatment,  the CD44+ALDH+  CSCs exhibited increased sensitivity to cisplatin and
etoposide, and radiotherapy. These findings illustrate the potential utility of CSCs as unique
cell targets for both chemotherapy and radiation therapy.
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7.2. CD133
First described in 1997, CD133 (Prominin 1) is a transmembrane glycoprotein expressed in
several normal stem cell populations and malignancies [51]. CD133 is localized to cellular
membrane protrusions and microvilli [52]. It is expressed in several solid malignancies includ-
ing brain, colon, liver, and lung, and has been purported as a unique, specific marker for
sarcomas [38]. In 2007, Zhou et al. demonstrated the presence of a CD133+ subpopulation in
3.5% of the native cells from a HEp-2 laryngeal cancer cell line. These CD133+ cells continued
to proliferate and expand the tumor cell population in sphere formation assays. In cell culture
assays, the majority of terminal cells did not express CD133, a finding consistent with the
criteria for CSC self-renewal as well as the capacity to give rise to phenotypically unique tumor
daughter cells [53]. More recent studies have supported these findings, suggesting the utility
of CD133 as a clinically relevant prognostic marker in HNSCC. Canis et al. demonstrated an
inversely proportional correlation between CD133 expression in primary tumors and overall
survival in addition to a positive correlation between CD133 expression and the presence of
lymph node metastases [54]. In addition, Yu et al. describe an oral cavity squamous cell
carcinoma-derived side population of cells with high expression of CD133 and ALDH showed
high tumorigenic capacity [55]. Cell viability assays revealed that these side populations of
cells were more chemoresistant to cisplatin, fluorouracil, or doxorubicin treatment when
compared to the major population of the same cell line. The researchers hypothesized that
CD133 may be crucial to modulation of chemosensitivity. They subsequently performed
lentiviral-mediated transduction in the side population of cells, which resulted in significant
decrease in expression of CD133 mRNA and protein. The silencing of CD133 decreased the
percentage of the side population in the cancer cell lines and decreased in vivo tumor growth.
Furthermore, cisplatin treatment of the CD133 knockdown population diminished cell inva-
sion and clonogenicity, demonstrating the enhanced sensitivity to chemotherapy by targeting
CD133. These findings support the role of HNSCC CSCs as novel therapeutic targets in the
development of chemotherapeutic drugs.
7.3. ALDH
ALDH is an intracellular enzyme most commonly found in the liver [47]. ALDH detoxifies
intracellular aldehydes through oxidation and may play a role in the differentiation of stem
cells by oxidizing retinol into retinoic acid. With regard to cancer, high ALDH activity has been
linked to subsets of multiple myeloma and acute myeloid leukemia [56]. Prior to its identifica-
tion with HNSCC, ALDH was labeled a putative CSC marker in both breast and colon cancer.
Ginestier et al. successfully used high ALDH activity to identify a tumorigenic breast cancer
cell fraction capable of self-renewal and generating heterogeneous tumors. In their study,
expression of ALDH as detected by immunohistochemistry correlated with a poorer prognosis
for breast carcinomas [57].
Expression of ALDH1 in inflammatory breast cancer has been put forth as an independent
predictor of early metastasis and decreased survival [58]. In 2009, Chen et al. published the
first study demonstrating that cells of ALDH1+ lineage have CSC properties and play a role in
self- renewal in HNSCC [3]. In a study by Clay et al., HNSCC cells were categorized and isolated
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based on either high or low ALDH activity and subsequently implanted into immunocompro-
mised mice. Cells with relatively high levels of ALDH represented a small percentage of cells
(1% to 7.8%), but gave rise to tumors from as few as 500 cells in 53% of implantations. In
contrast, only 8% of similar implantations with cells expressing low levels of ALDH formed
tumor. As a result, ALDH appears to be a relatively selective marker for HNSCC CSCs [56].
In a similar study, 87% of implantations with 1000 ALDH+CD44+ HNSCC cells generated
tumors, compared to only 13% of ALDH-CD44- cell implantations, despite utilizing ten times
more cells: 10, 000 [59]. ALDH+ cells have also been shown to exhibit higher expression levels
of stem cell-related, drug-resistance-associated, and epithelial-mesenchymal-transformation-
related (EMT) genes such as Snail [3]. In fact, Snail protein overexpression transformed
ALDH- cells to ALDH+ cells, resulting in increased invasion and tumorigenic properties [65].
Given this association with Snail and EMT, as well as the ability to recapitulate tumors in high
percentages after in vivo implantation in multiple studies, ALDH may be the most well-
established HNSCC CSC marker to date.
7.4. CD24 and CD10
CD24 is a mucin adhesion molecule for P-selectin and L1 expressed by pre-B lymphocytes and
neutrophils during cell development [47, 60]. CD24 expression has been shown to increase
tumor cell proliferation and further shown to regulate multiple cell properties which contrib-
ute to tumor growth and metastasis [60]. It has been correlated with increased spread of breast
cancer and has been further identified as a putative CSC marker in pancreatic, ovarian, and
colorectal cancers [61, 62]. CD24 has also been associated with tumorigenesis, tumor progres-
sion, and malignant transformation of stomach and gallbladder cancers [63]. In a study by Han
et al. CD24+CD44+ HNSCC cells were demonstrated to be more proliferative and invasive in
vitro and more tumorigenic in vivo. After implantation in immunodeficient mice,
CD24+CD44+ cells formed larger tumors than the CD24-CD44+ group. CD24+CD44+ cells were
also correlated with slightly increased resistance to chemotherapeutic agents [62]. CD24 is one
of the primary surface antigens involved in solid tumors and its role has been established in
various human epithelial neoplasias. However, the paucity of research concerning HNSCC
precludes its inclu- sion as a CSC biomarker at the present time.
CD10 is a zinc-dependent metalloendoprotease that cleaves signaling peptides and is found
in a wide range of normal tissues. It has been described as a potential marker for therapeutic
resistance and tumor recurrence in HNSCC [64]. As the field of CSCs remains in its infancy,
further investigation regarding the roles of CD24 and CD10 will better elucidate the role of
these proteins in HNSCC.
8. Clinical relevance of head and neck cancer stem cells
Today, few studies have evaluated patient HNSCC tumors or tissues and the correlation with
clinical data and outcomes. One barrier to the establishment of clinically significant CSC
markers in the head and neck region is secondary to the convention of amassing malignancies
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from various upper aerodigestive sites with distinctly diverse embryological and biological
characteristics [47]. As a result, there is little definitive data with regard to clinical implications
of CSCs within HNSCC, the primary exception being prognostic value. Furthermore, no single
biomarker for CSC cells in HNSCC has proven absolute in distinguishing this vital subpopu-
lation. The continued study of current prospective CSC markers in HNSCC, combined with
the investigation of putative CSC biomarkers from other malignancies, will undoubtedly
augment our knowledge and improve our understanding of the pathogenesis of HNSCC. In
addition, further knowledge regarding the biomarkers and regulation of normal, native stem
cells in the head and neck region will serve as a strong foundation for oncological research.
Ultimately, CSCs may prove to be useful diagnostic and prognostic markers for HNSCC,
guiding therapy and treatment through personalized approaches and interventions.
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